Dendritic cell immunotherapy: mapping the way

被引：780

作者：

Figdor, CG

de Vries, IJM

Lesterhuis, WJ

Melief, CJM

机构：

[1] Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands

[2] Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[3] Univ Med Ctr Leiden, Dept Immunohematol & Blood Transfus, NL-2300 RA Leiden, Netherlands

来源：

NATURE MEDICINE | 2004年 / 10卷 / 05期

关键词：

D O I：

10.1038/nm1039

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.

引用

页码：475 / 480

页数：6

共 50 条

[1] Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases [J].